Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Revenue (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed Revenue for 3 consecutive years, with $104.5 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 24.3% to $104.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $400.0 million through Dec 2025, up 28.95% year-over-year, with the annual reading at $400.0 million for FY2025, 28.95% up from the prior year.
  • Revenue hit $104.5 million in Q4 2025 for Immunocore Holdings, up from $103.7 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $104.5 million in Q4 2025 to a low of $54.7 million in Q1 2023.
  • Historically, Revenue has averaged $80.0 million across 3 years, with a median of $77.8 million in 2024.
  • Biggest five-year swings in Revenue: increased 19.8% in 2024 and later surged 33.16% in 2025.
  • Year by year, Revenue stood at $70.2 million in 2023, then increased by 19.8% to $84.1 million in 2024, then grew by 24.3% to $104.5 million in 2025.
  • Business Quant data shows Revenue for IMCR at $104.5 million in Q4 2025, $103.7 million in Q3 2025, and $98.0 million in Q2 2025.